We are live on ! Find out more
DCM

Defilade Capital Management Portfolio holdings

AUM $747M
This Fund
S&P 500
This Quarter Est. Return
+0.08%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$712M
AUM Growth
-$25.6M
Cap. Flow
-$2.03M
Cap. Flow %
-0.29%
Top 10 Hldgs %
52.57%
Holding
42
New
9
Increased
12
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$53.1M
2
BDX icon
Becton Dickinson
BDX
+$36.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$27.9M
4
PTCT icon
PTC Therapeutics
PTCT
+$26.6M
5
HSIC icon
Henry Schein
HSIC
+$23.5M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$52M
2
NVS icon
Novartis
NVS
+$50M
3
STE icon
Steris
STE
+$34.3M
4
XNCR icon
Xencor
XNCR
+$21.7M
5
PACS icon
PACS Group
PACS
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
1
Zimmer Biomet
ZBH
$19.3B
$52.4M 7.35%
+579,161
New +$53.1M
HSIC icon
2
Henry Schein
HSIC
$10.1B
$46M 6.46%
624,037
+303,615
+95% +$23.5M
BDX icon
3
Becton Dickinson
BDX
$51.8B
$43.9M 6.16%
279,210
+198,003
+244% +$36.3M
PFE icon
4
Pfizer
PFE
$161B
$41.1M 5.77%
1,464,129
-739,375
-34% -$19.7M
DXCM icon
5
DexCom
DXCM
$33.6B
$33.8M 4.75%
538,762
+293,881
+120% +$20.5M
ICUI icon
6
ICU Medical
ICUI
$4.49B
$32.8M 4.61%
254,291
-86,454
-25% -$12.4M
INSM icon
7
Insmed
INSM
$27.2B
$31.9M 4.48%
194,909
+144,909
+290% +$22.3M
ISRG icon
8
Intuitive Surgical
ISRG
$131B
$31.2M 4.38%
67,681
+22,019
+48% +$11.1M
RVMD icon
9
Revolution Medicines
RVMD
$46.2B
$30.7M 4.31%
315,972
-47,482
-13% -$4.79M
GMED icon
10
Globus Medical
GMED
$11.2B
$30.5M 4.29%
354,350
+87,138
+33% +$7.82M
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.9B
$27.7M 3.88%
+209,932
New +$27.9M
DNLI icon
12
Denali Therapeutics
DNLI
$3.93B
$26.1M 3.67%
1,359,969
+703,256
+107% +$14M
PTCT icon
13
PTC Therapeutics
PTCT
$6.07B
$25.6M 3.6%
+376,165
New +$26.6M
OLMA icon
14
Olema Pharmaceuticals
OLMA
$949M
$22.4M 3.15%
1,504,536
+269,902
+22% +$6.01M
ELAN icon
15
Elanco Animal Health
ELAN
$12.5B
$22.3M 3.13%
931,121
+529,838
+132% +$13M
PACS icon
16
PACS Group
PACS
$7.03B
$19.4M 2.72%
604,180
-541,305
-47% -$19.9M
LLY icon
17
Eli Lilly
LLY
$1.06T
$19M 2.67%
20,696
-11,254
-35% -$11.4M
LNTH icon
18
Lantheus
LNTH
$6.58B
$18.9M 2.66%
+249,401
New +$17.9M
ITGR icon
19
Integer Holdings
ITGR
$4.26B
$18.7M 2.63%
+213,027
New +$18.1M
BIIB icon
20
Biogen
BIIB
$32.7B
$17.7M 2.48%
96,289
-65,703
-41% -$12.1M
EVMN
21
Evommune Inc
EVMN
$512M
$15.6M 2.19%
678,589
+463,171
+215% +$10.5M
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.49B
$14.6M 2.05%
+761,905
New +$16.6M
COGT icon
23
Cogent Biosciences
COGT
$6.37B
$13.6M 1.91%
352,590
-216,029
-38% -$7.98M
NUVL
24
DELISTED
Nuvalent
NUVL
$13.3M 1.87%
129,950
-139,093
-52% -$14.2M
OCUL icon
25
Ocular Therapeutix
OCUL
$2.37B
$12.6M 1.77%
1,487,645
+805,982
+118% +$7.68M
1
2

Similar funds

BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
PCM
Permanent Capital Management Chicago, Illinois $747M AUM 17.94% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $748M AUM 27.21% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $745M AUM 23.99% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $745M AUM 25.89% 1-Year Est. Return
CCME
CIBC Capital Markets (Europe) Luxembourg $745M AUM

Defilade Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Defilade Capital Management held 42 positions worth $712M, down 3.5% from $738M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Defilade Capital Management's Q1 2026 filing shows 9 new, 12 increased, 10 reduced and 11 closed positions. Its largest new stake was Zimmer Biomet: 579,161 shares worth $52.4M. The largest sale was AbbVie, an estimated $52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Defilade Capital Management's largest Q1 2026 buy was Zimmer Biomet: 579,161 shares worth $52.4M.
  • Defilade Capital Management added most to Becton Dickinson in Q1 2026, an estimated $36.3M increase.
  • Defilade Capital Management's biggest Q1 2026 reduction was PACS Group, cutting an estimated $19.9M.
  • Defilade Capital Management fully exited AbbVie in Q1 2026, selling an estimated $52M.
  • Defilade Capital Management's ten largest holdings make up 53% of its $712M portfolio in Q1 2026.
  • Defilade Capital Management opened 9 new positions and closed 11 in Q1 2026.
  • Defilade Capital Management's portfolio value fell 3.5% quarter-over-quarter to $712M.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.